Work

Quantitative CT of Normal Lung Parenchyma and Small Airways Disease Topologies are Associated With COPD Severity and Progression

Year: 2023

Type: preprint

Abstract: Objectives Small airways disease (SAD) is a major cause of airflow obstruction in COPD patients, and has been identified as a precursor to emphysema. Although the amount of SAD in the lungs can be quantified using our Parametric Response Mapping (PRM) approach, the full breadth of this readout as a measure of emphysema and COPD progression has yet to be explored. We evaluated topological features of PRM-derived normal parenchyma and SAD as surrogates of emphysema and predictors of spirometric decline. Materials and Methods PRM metrics of normal lung (PRM Norm ) and functional SAD (PRM fSAD ) were generated from CT scans collected as part of the COPDGene study (n=8956). Volume density (V) and Euler-Poincaré Characteristic (χ) image maps, measures of the extent and coalescence of pocket formations (i.e., topologies), respectively, were determined for both PRM Norm and PRM fSAD . Association with COPD severity, emphysema, and spirometric measures were assessed via multivariable regression models. Readouts were evaluated as inputs for predicting FEV 1 decline using a machine learning model. Results Multivariable cross-sectional analysis of COPD subjects showed that V and χ measures for PRM fSAD and PRM Norm were independently associated with the amount of emphysema. Readouts χ fSAD (β of 0.106, p<0.001) and V fSAD (β of 0.065, p=0.004) were also independently associated with FEV 1 % predicted. The machine learning model using PRM topologies as inputs predicted FEV 1 decline over five years with an AUC of 0.69. Conclusions We demonstrated that V and χ of fSAD and Norm have independent value when associated with lung function and emphysema. In addition, we demonstrated that these readouts are predictive of spirometric decline when used as inputs in a ML model. Our topological PRM approach using PRM fSAD and PRM Norm may show promise as an early indicator of emphysema onset and COPD progression.

Source: medRxiv

DOI: 10.1101/2023.05.26.23290532